Is there any relationship between actual benefit an< added value of drugs and pharmacovigilance alerts?

摘要

For each new medicine in France, after drug approval by the French Drug Agency (Agence Francaise de Securite Sanitaire des Produits de Sante), the French National Authority for Health [Haute Autorite de Sante (HAS)] issues an opinion for or against including it in the basket of products qualifying for reimbursement [1]. On one hand, HAS advises public decision makers on reimbursement and pricing.On the other, it informs practitioners about the real value of a new drug to individuals and society. The two main criteria used are the 'Actual Benefit' (AB) and the 'Improvement in Actual Benefit', also called 'added value' (IAB) of every drug.